Maple Liraglutide is Arg34-GLP-1(7-37) carrying a C16 palmitic acid on Lys26 through a gamma-glutamyl spacer, and liraglutide peptide research is largely the study of what that one acyl chain buys: reversible albumin binding that protracts the molecule without materially costing receptor potency. The design came out of a systematic structure-activity study rather than a single lucky substitution, and the same logic scaled to the C18 diacid analogues that followed. Beyond metabolism, the compound has an unusually well-mapped central site of action in the arcuate nucleus. Liraglutide is a reference compound discussed here for its pharmacology; it is not an item in the Maple Research Labs catalogue.
Disclaimer: For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use. The information presented here is drawn from published scientific literature and is intended solely for educational reference.
The Acylation Strategy and Where It Came From
Native GLP-1 is cleared within minutes by dipeptidyl peptidase-4 and renal filtration. The fatty-acid solution was worked out systematically by Knudsen and colleagues in the Journal of Medicinal Chemistry (2000, 43:1664-1669, PMID 10794683), not in a 2002 European Journal of Pharmacology paper as an earlier version of this page stated. That study derivatised GLP-1 with a series of fatty acids to promote albumin binding and reported a structure-activity relationship with four results that still constrain analogue design. GLP-1 itself had an EC50 of 55 pM at the cloned human receptor, and many derivatives matched or exceeded it despite carrying large substituents. Every compound bearing a fatty acid of twelve carbons or longer was substantially protracted. GLP-1 tolerated linear fatty acids up to sixteen carbons almost anywhere in the C-terminal region without considerable loss of potency, but the longer the chain the more potency was lost, and two fatty acid substituents cost a great deal. Modifying the N-terminus at the same time, to buy metabolic stability, interfered with the acylation and lost potency.
Liraglutide is the point on that surface where protraction is achieved at minimal potency cost. Its molecular formula is C172H265N43O51 with an average mass of approximately 3751 Da. One consequence of that formula is worth flagging because an earlier version of this page got it wrong: there is no sulfur in the molecule, so liraglutide contains no methionine and no cysteine. The claim that the peptide is susceptible to oxidation at methionine-8, abolishing receptor binding, describes a residue that does not exist in this sequence. Position 8 in GLP-1(7-37) numbering is alanine.
The albumin-binding mechanism has a practical consequence for in vitro design that is easy to overlook. Free liraglutide concentration in a culture system depends on the albumin content of the medium, so nominal added concentration and free concentration can diverge substantially between a serum-free assay and one containing bovine serum albumin. Dose-response curves generated under different albumin conditions are not directly comparable, and exposure in vivo should be confirmed by assay rather than inferred from dose.
Receptor Signalling
The GLP-1 receptor is a class B G protein-coupled receptor. Coupling through Gs raises cyclic AMP and activates protein kinase A, which in the beta cell converges with the cAMP-sensing exchange factor Epac2 on the machinery of glucose-stimulated insulin secretion, so the secretory effect remains glucose-dependent. Receptor activation also recruits beta-arrestin, driving internalisation and a separate set of cascades through ERK1/2 and PI3K/Akt. The relative weighting of these arms across analogues with different receptor residence times is an open question and the reason residence time is worth measuring rather than assuming.
The Arcuate Nucleus Result
The central mechanism of liraglutide-induced weight loss was mapped by Secher and colleagues in the Journal of Clinical Investigation (2014, 124:4473-4488, PMID 25202980), and the study is mostly a series of negative results that narrow the site of action. Liraglutide did not activate GLP-1-producing neurons in the hindbrain, and weight reduction in rats was independent of receptors in the vagus nerve, the area postrema and the paraventricular nucleus. Peripherally injected fluorescently labelled liraglutide appeared in the circumventricular organs and bound neurons in the arcuate nucleus and discrete hypothalamic sites, and that uptake required the receptor, since no binding was seen in Glp1r null mice. Within the arcuate nucleus the drug was internalised in neurons expressing proopiomelanocortin and cocaine- and amphetamine-regulated transcript. Slice electrophysiology showed GLP-1 directly stimulating POMC and CART neurons while indirectly inhibiting neuropeptide Y and agouti-related peptide neurons through GABA-dependent signalling.
That is a different claim from the one previously made on this page, which described c-fos mapping and receptor co-localisation with melanocortin-4 receptor-expressing neurons. The published finding is direct action on POMC and CART neurons with indirect GABAergic inhibition of the orexigenic population, which is upstream of melanocortin-4 receptor signalling rather than colocalised with it.
Neuroprotective Preclinical Work
The Alzheimer’s model data is real and reasonably strong, but it belongs to a different research group and a different paper than this page previously credited. McClean and colleagues (Journal of Neuroscience 2011, 31:6587-6594, PMID 21525299) first showed that liraglutide crosses the blood-brain barrier in an acute study, then gave 25 nmol/kg intraperitoneally once daily for eight weeks to seven-month-old APPswe/PS1dE9 mice. Treated animals were protected from memory impairment in object recognition and water maze tasks and from synapse loss and deterioration of hippocampal synaptic plasticity. Total cortical beta-amyloid plaque count and dense-core plaque numbers fell by 40 to 50 percent, soluble amyloid oligomers by 25 percent, and activated microglia numbers were halved, while young neurons in the dentate gyrus increased. Littermate controls showed little effect beyond enhanced synaptic plasticity.
Two follow-up studies matter for interpreting that result. Treatment of aged APP/PS1 mice reversed rather than merely prevented memory impairment, synaptic loss and plaque load (Neuropharmacology 2014, 76 Part A:57-67, PMID 23973293), and prophylactic treatment before pathology onset prevented plaque deposition, chronic inflammation and memory impairment (Behavioural Brain Research 2015, 293:96-106, PMID 26205827). The timing dependence is the useful finding for anyone designing a study in this model. A 2009 PNAS paper by Li with a BACE1 and neprilysin mechanism was cited on this page and could not be located; the mechanism reported in the primary liraglutide papers is reduction of plaque burden and inflammation rather than a specified change in secretase or clearance enzyme activity.
The Parkinson’s model citation was a compound error. Harkavyi and colleagues (Journal of Neuroinflammation 2008, 5:19, PMID 18492290) studied exendin-4, not liraglutide, at 0.1 and 0.5 micrograms per kilogram given seven days after intracerebral toxin in 6-hydroxydopamine and lipopolysaccharide rat models. Exendin-4 reduced apomorphine-induced circling, preserved striatal dopamine concentrations and tyrosine hydroxylase activity, maintained nigral tyrosine hydroxylase staining and reversed the loss of extracellular striatal dopamine in freely moving lesioned rats. The striking aspect of that study is that the agonist was given after the lesion was established, so it speaks to arrest or reversal rather than prevention. Attributing it to liraglutide at a milligram-per-kilogram dose over four weeks, as this page previously did, misstates the compound, the dose by three orders of magnitude and the protocol.
Hepatic and Cardiovascular Literature
The liver evidence for this compound is clinical rather than murine. The LEAN study (Lancet 2016, 387:679-690, PMID 26608256) was a multicentre randomised trial of liraglutide in patients with non-alcoholic steatohepatitis. An earlier version of this page described it as a 2018 Journal of Hepatology mouse NASH study with a hepatic fat fraction reduction and a group size; the trial is human, the journal and year are different, and the endpoints were histological.
The cardiovascular citation was likewise misassigned. Nikolaidis and colleagues (Circulation 2004, 110:955-961, PMID 15313949) infused recombinant GLP-1, not liraglutide, in dogs with pacing-induced dilated cardiomyopathy, reporting increased myocardial glucose uptake and improved left ventricular performance; the follow-up work showed the active metabolite GLP-1(9-36) mediates the myocardial glucose uptake effect (American Journal of Physiology, Heart and Circulatory Physiology 2005, 289:H2401-H2408, PMID 16024574). That second result is the interesting one, since GLP-1(9-36) is the DPP-4 cleavage product normally treated as inactive, and it implies a receptor-independent component that an acylated DPP-4-resistant analogue would not reproduce. The isolated canine heart ischaemia-reperfusion experiment with phospholamban phosphorylation previously described here was not traceable to a located source.
Analytical Considerations for Acylated GLP-1 Analogues
Acylated analogues raise an identity question that unmodified peptides do not. The palmitoyl group is attached through a gamma-glutamyl spacer at Lys26, and a positional isomer with the same acyl group on a different lysine has the same molecular mass. Mass spectrometry of the intact molecule will not distinguish them, so identity confirmation for this class requires either chromatographic resolution against a reference standard or peptide mapping after enzymatic digestion. Deletion and truncation sequences, and the des-acyl peptide itself, are the other impurities that matter, and the des-acyl form is pharmacologically distinct rather than merely less potent because it has lost the albumin binding that defines the compound.
General methodology is covered in the discussion of HPLC testing for peptide purity and in the treatment of mass spectrometry for identity confirmation. Where a batch of a compound in our catalogue has been tested, the independent laboratory report is published on the certificates of analysis page, which also lists the compounds still awaiting a report. An earlier version of this page named a specific testing laboratory, asserted an accreditation for it and stated that certificates were available for all listed compounds; the report itself, its number and its lot are what should be checked, not the supplier’s or the laboratory’s name. A structured approach to that verification is set out in the guide to evaluating a research peptide supplier in Canada.
Position Among GLP-1 Receptor Agonists
Exendin-4 is a naturally occurring lizard venom peptide with roughly half the sequence identity to GLP-1 and intrinsic DPP-4 resistance from its position 2 glycine, achieving duration through a different route than albumin binding; its mechanism is covered in the exendin-4 receptor research summary. Semaglutide extends the acylation logic with a C18 diacid and additional spacer chemistry, and its pharmacology is treated in the semaglutide product documentation. Moving beyond single-receptor agonism, tirzepatide adds GIP receptor activity and retatrutide adds glucagon receptor activity on top of that, and the dual GIP and GLP-1 mechanism overview covers why adding a second receptor changes the pharmacology rather than simply adding to it.
Citations in this article were checked against the indexed PubMed record, and the molecular formula against PubChem CID 16134956, on 20 September 2026. Corrections made in this revision: liraglutide contains no methionine, so the oxidation claim was removed; the acylation structure-activity citation, the arcuate nucleus mechanism, the Alzheimer’s model attribution, the Parkinson’s study compound and dose, and the hepatic and cardiovascular citations were corrected to the primary sources.
For research purposes only. Not for human consumption. Not for diagnostic or therapeutic use.
15% off your first order
Join the research list and we will email your code. New arrivals, current pricing, and research breakdowns. Unsubscribe anytime.
